E J T Rutgers

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. ncbi Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases
    Emiel J T Rutgers
    Department of Surgery, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 26:698-702. 2008
  2. ncbi Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial
    Marijke R Wevers
    Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, PO Box 90203, 1006 BE Amsterdam, The Netherlands
    BMC Cancer 11:6. 2011
  3. ncbi Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Surg Oncol 17:1854-61. 2010
  4. ncbi Sentinel node micrometastasis in breast cancer
    E J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Surg 91:1241-2. 2004
  5. ncbi Ductal carcinoma in situ of the breast; diagnostic assessment and treatment
    E J Th Rutgers
    Department of Surgery, Pathology, and Radiation Oncology, Netherlands Cancer Institute, Amsterdam
    Scand J Surg 91:268-72. 2002
  6. ncbi Guidelines to assure quality in breast cancer surgery
    E J Th Rutgers
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Surg Oncol 31:568-76. 2005
  7. ncbi Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more?
    E J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek ziekenhuis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 40:182-6. 2004
  8. ncbi Follow-up care in breast cancer
    Emiel J Rutgers
    Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Expert Rev Anticancer Ther 4:212-8. 2004
  9. ncbi Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group
    Emiel J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Breast Cancer Res 6:165-9. 2004
  10. ncbi The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
    Emiel Rutgers
    The Netherlands Cancer Institute, Department of Surgery, Amsterdam, The Netherlands
    Eur J Cancer 47:2742-9. 2011

Collaborators

Detail Information

Publications33

  1. ncbi Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases
    Emiel J T Rutgers
    Department of Surgery, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 26:698-702. 2008
    ..Protocols that identify lymph node metastasis, from which the clinical relevance is known, are warranted. Unnecessary lymph node dissections should be avoided...
  2. ncbi Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial
    Marijke R Wevers
    Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, PO Box 90203, 1006 BE Amsterdam, The Netherlands
    BMC Cancer 11:6. 2011
    ..The aim of this study is to determine the effect of RGCT on treatment decisions and on psychosocial health...
  3. ncbi Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Surg Oncol 17:1854-61. 2010
    ..The aim of the current substudy was to evaluate the identification rate and the nodal involvement...
  4. ncbi Sentinel node micrometastasis in breast cancer
    E J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Surg 91:1241-2. 2004
  5. ncbi Ductal carcinoma in situ of the breast; diagnostic assessment and treatment
    E J Th Rutgers
    Department of Surgery, Pathology, and Radiation Oncology, Netherlands Cancer Institute, Amsterdam
    Scand J Surg 91:268-72. 2002
  6. ncbi Guidelines to assure quality in breast cancer surgery
    E J Th Rutgers
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Surg Oncol 31:568-76. 2005
    ..The outcome of the different procedures can be measured according to simple criteria and prospective registration. All possible surgical procedures, the indication-objectives, the training-objectives and outcome measures are described...
  7. ncbi Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more?
    E J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek ziekenhuis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 40:182-6. 2004
  8. ncbi Follow-up care in breast cancer
    Emiel J Rutgers
    Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Expert Rev Anticancer Ther 4:212-8. 2004
    ..For more complex issues, such as debilitating functional treatment regimens, estrogen deprivation symptoms, pregnancy after breast cancer or symptoms suspicious for a relapse, an experienced oncologist should be at hand...
  9. ncbi Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group
    Emiel J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Breast Cancer Res 6:165-9. 2004
    ....
  10. ncbi The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
    Emiel Rutgers
    The Netherlands Cancer Institute, Department of Surgery, Amsterdam, The Netherlands
    Eur J Cancer 47:2742-9. 2011
    ..We present the results of the pilot phase consisting of first 800 patients included...
  11. ncbi Excision biopsy of breast lesions changes the pattern of lymphatic drainage
    S H Estourgie
    Department of Surgery, Academic Medical Centre, Meibergdreef 9, Amsterdam, The Netherlands
    Br J Surg 94:1088-91. 2007
    ..The aim was to validate the sentinel node biopsy procedure in women who had previous breast excision biopsy by means of determining the reproducibility of lymphoscintigraphy after surgery...
  12. ncbi Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy
    P Meijnen
    Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Br J Surg 94:952-6. 2007
    ..The data were used to select criteria for patients in whom sentinel node (SN) biopsy might be indicated...
  13. ncbi Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer
    M E Straver
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Br J Surg 97:1226-31. 2010
    ..The aim was to assess a new surgical method for evaluating the axillary response to chemotherapy...
  14. ncbi The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
    S Mook
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Ann Oncol 21:717-22. 2010
    ..The aim of this study was to evaluate the prognostic value of the 70-gene prognosis signature for early events in postmenopausal patients...
  15. ncbi Validation of 70-gene prognosis signature in node-negative breast cancer
    J M Bueno-de-Mesquita
    Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Breast Cancer Res Treat 117:483-95. 2009
    ....
  16. ncbi Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up
    J G Schrama
    Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam
    Ann Oncol 13:689-98. 2002
    ....
  17. ncbi Stage of breast cancers found during the surveillance of women with a familial or hereditary risk
    R Kaas
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
    Eur J Surg Oncol 34:501-7. 2008
    ..To compare the breast cancer stages found during MG alone surveillance in women at increased risk with those detected in a program where MRI was added...
  18. ncbi Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
    M Knauer
    Division of Diagnostic Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam NL 1066CX, The Netherlands
    Br J Cancer 103:1788-93. 2010
    ..However, the majority of patients does not recur and might thus be overtreated with adjuvant systemic therapy. We investigated whether the 70-gene MammaPrint signature identifies HER-2-positive patients with favourable outcome...
  19. ncbi The hidden sentinel node in breast cancer
    P J Tanis
    Department of Surgery, The Netherlands Cancer Institute, Amsterdam
    Eur J Nucl Med Mol Imaging 29:305-11. 2002
    ..Delayed imaging and re-injection of the radioactive tracer increase the visualisation rate. The non-visualised sentinel node can be identified intraoperatively in more than half of the patients...
  20. ncbi Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS
    N Bijker
    Department of Radiation Oncology, The Netherlands Cancer Institute Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Cancer 87:615-20. 2002
    ..Selection of patients may explain the differences in outcome of the randomised patients, and those not-entered. Thus, the results of this trial may not be applicable to all patients with ductal carcinoma in situ...
  21. ncbi The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer
    R Kaas
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Ziekenhuis Plesmanlaan, Amsterdam, The Netherlands
    Br J Cancer 88:707-10. 2003
    ..045). In conclusion, metachronous CBCs developing after 1-3 years of tamoxifen treatment are more often ER-negative breast cancers. So far this does not seem to have a major impact on survival...
  22. ncbi Adjuvant therapy for breast cancer
    S Rodenhuis
    Departments of Medical Oncology and Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Surg 93:1443-5. 2006
  23. ncbi Axillary and extra-axillary lymph node recurrences after a tumor-negative sentinel node biopsy for breast cancer using intralesional tracer administration
    Iris M C van der Ploeg
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands
    Ann Surg Oncol 15:1025-31. 2008
    ..The objective of the present study of sentinel node-negative breast cancer patients was to determine the lymph node recurrence rates in the axilla and elsewhere, the false-negative rates, and the survival...
  24. ncbi Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy
    Maartje C van Rijk
    Department of Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands
    Ann Surg Oncol 13:31-5. 2006
    ..The aims of this study were to evaluate the sensitivity of preoperative ultrasonography and fine-needle aspiration cytology for detecting axillary metastases and to assess how often sentinel node biopsy could be avoided...
  25. ncbi Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection
    Maartje C van Rijk
    Department of Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands
    Ann Surg Oncol 13:475-9. 2006
    ..In our institute, sentinel lymph node biopsy is performed before neoadjuvant chemotherapy. The aim of this study was to evaluate our experience with this approach...
  26. ncbi Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
    Jolien M Bueno de Mesquita
    Department of Pathology, Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
    Lancet Oncol 8:1079-87. 2007
    ....
  27. ncbi Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk
    Dorien W Voskuil
    Division of Experimental Therapy and the Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nutr Cancer 60:342-53. 2008
    ..However, lycopene effects were discordant between the 2 study populations showing beneficial effects in high-risk healthy women but not in breast cancer survivors...
  28. ncbi Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition
    Mieke Kriege
    The Rotterdam Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands
    Cancer 106:2318-26. 2006
    ..As results of these subsequent screening rounds were most predictive for long-term effects, the authors expect that this screening program will contribute to a decrease of breast cancer mortality in these high-risk women...
  29. ncbi Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience
    Eduard L A R Mutsaerts
    Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
    J Gastrointest Surg 9:178-86. 2005
    ..Our data suggest there is no strong predictor of survival. Survival seems to decrease with increasing number of metastases found on computed tomography...
  30. ncbi Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition
    Mieke Kriege
    Rotterdam Family Cancer Clinic, Department of Medical Oncology, Erasmus Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    N Engl J Med 351:427-37. 2004
    ..4 percent (P<0.001) and 56.4 percent (P=0.001) in the two control groups. CONCLUSIONS: MRI appears to be more sensitive than mammography in detecting tumors in women with an inherited susceptibility to breast cancer...
  31. ncbi Individualization of therapy using Mammaprint: from development to the MINDACT Trial
    Stella Mook
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Genomics Proteomics 4:147-55. 2007
    ....
  32. ncbi Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer
    Mieke Kriege
    Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Breast Cancer Res Treat 100:109-19. 2006
    ..227) and for women with a low breast density (0.237). CONCLUSIONS: This report supports the earlier recommendation that MRI should be a standard screening method for breast cancer in BRCA1/2 mutation carriers...
  33. ncbi Are short-term or long-term recurrence rates more important in breast cancer screening?
    Emiel J T Rutgers
    Ann Intern Med 149:357; author reply 357-8. 2008